000282352 001__ 282352
000282352 005__ 20240229155039.0
000282352 0247_ $$2doi$$a10.3390/cancers15164132
000282352 0247_ $$2pmid$$apmid:37627160
000282352 0247_ $$2pmc$$apmc:PMC10453103
000282352 0247_ $$2altmetric$$aaltmetric:153385627
000282352 037__ $$aDKFZ-2023-01736
000282352 041__ $$aEnglish
000282352 082__ $$a610
000282352 1001_ $$aZitricky, Frantisek$$b0
000282352 245__ $$aConditional Survival in Prostate Cancer in the Nordic Countries Elucidates the Timing of Improvements.
000282352 260__ $$aBasel$$bMDPI$$c2023
000282352 3367_ $$2DRIVER$$aarticle
000282352 3367_ $$2DataCite$$aOutput Types/Journal article
000282352 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1693227331_1865
000282352 3367_ $$2BibTeX$$aARTICLE
000282352 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282352 3367_ $$00$$2EndNote$$aJournal Article
000282352 500__ $$a#LA:C020#
000282352 520__ $$aThe incidence of prostate cancer (PC) increased vastly as a result of prostate-specific antigen (PSA) testing. Survival in PC improved in the PSA-testing era, but changes in clinical presentation have hampered the interpretation of the underlying causes.We analyzed survival trends in PC using data from the NORDCAN database for Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE) by analyzing 1-, 5- and 10-year relative survival and conditional relative survival over the course of 50 years (1971-2020).In the pre-PSA era, survival improved in FI and SE and improved marginally in NO but not in DK. PSA testing began toward the end of the 1980s; 5-year survival increased by approximately 30%, and 10-year survival improved even more. Conditional survival from years 6 to 10 (5 years) was better than conditional survival from years 2 to 5 (4 years), but by 2010, this difference disappeared in countries other than DK. Survival in the first year after diagnosis approached 100%; by year 5, it was 95%; and by year 10, it was 90% in the best countries, NO and SE.In spite of advances in diagnostics and treatment, further attention is required to improve PC survival.
000282352 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000282352 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000282352 650_7 $$2Other$$aPSA screening
000282352 650_7 $$2Other$$aperiodic survival
000282352 650_7 $$2Other$$aprognosis
000282352 650_7 $$2Other$$atreatment
000282352 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000282352 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b2
000282352 7001_ $$aHemminki, Otto$$b3
000282352 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b4$$eLast author$$udkfz
000282352 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers15164132$$gVol. 15, no. 16, p. 4132 -$$n16$$p4132$$tCancers$$v15$$x2072-6694$$y2023
000282352 909CO $$ooai:inrepo02.dkfz.de:282352$$pVDB
000282352 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000282352 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000282352 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000282352 9141_ $$y2023
000282352 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-24T07:56:58Z
000282352 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000282352 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000282352 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000282352 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000282352 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000282352 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000282352 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000282352 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000282352 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000282352 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000282352 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000282352 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000282352 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000282352 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000282352 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000282352 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000282352 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000282352 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000282352 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000282352 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000282352 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000282352 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x2
000282352 980__ $$ajournal
000282352 980__ $$aVDB
000282352 980__ $$aI:(DE-He78)B062-20160331
000282352 980__ $$aI:(DE-He78)HD01-20160331
000282352 980__ $$aI:(DE-He78)C020-20160331
000282352 980__ $$aUNRESTRICTED